Fixed Drug Eruption: Recurring Medication Reaction

Clinical Overview

Fixed Drug Eruption (FDE) is a recurrent, drug-induced mucocutaneous reaction characterized by eruption at identical sites each time the causative drug is ingested. Lesions appear predictably within 30 minutes to 8 hours after re-exposure and resolve within days to weeks after drug discontinuation, leaving post-inflammatory hyperpigmentation. FDE accounts for 5-11% of adverse drug reactions and 22-35% of cutaneous drug reactions, making it the most common recurrent drug eruption. While generally benign, FDE can indicate serious systemic involvement if mucosal surfaces are involved.

Epidemiology & Risk Factors

FDE occurs in approximately 1-2% of patients taking medications, though exact incidence is difficult to establish due to under-recognition. Antibiotics cause approximately 50% of cases, with trimethoprim-sulfamethoxazole (TMP-SMX) the single most common culprit (25-30% of all FDE cases). Other frequent triggers include acetaminophen, NSAIDs, tetracyclines, phenolphthalein (now removed from most markets), oral contraceptives, anticonvulsants, and allopurinol. Antimicrobial agents generally account for 50-60% of all FDE cases. Recurrent episodes with the same drug are nearly universal—reported in 99% of patients with identified causative agents.

Pathophysiology

FDE results from tissue-resident memory T cells (T_RM) that persist at sites of previous drug reaction. Upon re-exposure to the causative drug, local T cells rapidly activate and proliferate, releasing inflammatory cytokines (IFN-gamma, TNF-alpha, IL-2) that recruit additional T cells and activate keratinocytes and endothelial cells. The drug (or its metabolite) is processed by dendritic cells and presented on MHC molecules. CD8+ T cells are most important in FDE pathogenesis, distinguishing it from T cell-mediated but non-resident reactions. This explains the remarkable predictability of lesion location—the same immune cells reactivate in the same anatomic sites. The predilection for acral and mucosal surfaces reflects preferential homing of T_RM to these locations.

Clinical Presentation & Classification

FDE presents as solitary or multiple lesions that recur at identical sites with each drug re-exposure. Solitary lesions are most common, occurring in 40-50% of patients; multiple simultaneous lesions occur in 20-30% of cases, and rarely, generalized FDE affects >10% BSA. Morphology varies:

• Erythematous type: Round to oval erythematous patches/plaques, most common (70-80% of cases)
• Bullous type: Blistering within lesions (10-15% of cases), particularly with antibiotics
• Lichen planus-like: Polygonal, violaceous papules resembling lichen planus
• Pigmented type: Post-inflammatory hyperpigmentation at site of previous lesions
• Urticarial type: Urticaria-like lesions

Genital involvement (glans penis in males, vulva/vagina in females) is the most common mucosal site, occurring in 25-40% of cases. Oral mucosa involvement is less common (15-25%). Systemic symptoms are absent unless mucosal involvement is extensive.

Diagnosis & Workup

Diagnosis is primarily clinical: characteristic recurrence at identical sites with drug re-exposure. Skin biopsy is helpful when diagnosis is uncertain. Histology shows lichenoid inflammation with interface dermatitis, vasculitis, and variable keratinocyte necrosis depending on type. The inflammatory infiltrate is predominantly CD8+ T cells. Direct immunofluorescence is negative.

Key diagnostic criteria:

• Eruption at same anatomic site(s) with each drug exposure
• Temporal relationship to drug ingestion (within hours to 8 hours)
• Resolution following drug discontinuation
• Positive re-challenge (may not be advisable with mucosal involvement)
• Biopsy consistent with drug reaction (if needed)

Drug causality can be assessed using standardized algorithms like the Naranjo score (>7 suggests probable relationship) or ALDEN algorithm. Patch testing is not standardized for FDE but may be considered in research settings.

Treatment Algorithm

First-line: Drug discontinuation. This is the definitive treatment. Symptoms resolve within 3-7 days once the causative drug is stopped. Identify and confirm causative agent—review all medications, supplements, and over-the-counter products taken before FDE onset.

Symptomatic management: Topical corticosteroids (Class III-IV potency) accelerate healing and reduce inflammation. Apply twice daily for 3-7 days. For mild cases, emollients alone may suffice. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are effective alternatives, particularly for facial lesions where steroid atrophy is a concern.

Mucosal involvement: Topical corticosteroids (betamethasone rinse or triamcinolone paste applied directly to erosions 3-4 times daily) reduce pain and accelerate healing. Topical anesthetics (benzocaine, viscous lidocaine) may be needed for severe oral involvement affecting eating or swallowing.

Systemic treatment (rarely needed): For extensive generalized FDE (>10% BSA) or severe mucosal involvement, systemic corticosteroids (prednisone 0.5-1 mg/kg/day tapered over 1-2 weeks) accelerate resolution. Systemic antibiotics are not needed unless superinfection occurs (rare).

Post-inflammatory hyperpigmentation management: This is common, particularly in darker skin types. Reassure patients it typically fades over 3-6 months. Sunscreen (SPF 30+) may prevent further darkening. Hyperpigmentation that persists >6 months may respond to hydroquinone 4% or combination creams (hydroquinone/tretinoin/fluocinolone), though response is variable.

Prognosis & Complications

Prognosis is excellent with drug discontinuation. Recurrence is almost certain if the drug is re-introduced—reported in 95-99% of patients. Scarring is rare unless bullous lesions become infected. Most complications relate to delayed diagnosis leading to unnecessary investigations or drug re-challenge. Mucosal scarring is possible with repeated, severe mucosal involvement, but this is uncommon. Post-inflammatory hyperpigmentation is cosmetically bothersome but temporary.

When to See a Dermatologist

Seek evaluation if you develop recurrent lesions at the same site, particularly if they correlate with medication use. Dermatologists can confirm diagnosis and identify the causative agent, potentially saving you from unnecessary testing. If mucosal involvement is severe or you develop systemic symptoms, prompt evaluation is important to rule out more serious drug reactions (SJS/TEN).

Frequently Asked Questions

Why do lesions keep appearing in the same spot?

Your immune system "remembers" the location of the original drug reaction. Tissue-resident memory T cells persist at the site where the first reaction occurred. When you take the drug again, these local T cells rapidly reactivate before your immune system's systemic response kicks in, causing lesions exactly where they appeared before.

Is it dangerous to take the drug once I know the cause?

No, it's not dangerous in the sense that FDE alone is not life-threatening. However, you should avoid the drug permanently since recurrence is nearly certain. More importantly, if you experienced severe symptoms (especially with mucosal involvement), you cannot distinguish whether future re-exposure would cause mild FDE or evolve into more serious reactions like SJS/TEN. It's safest to avoid the drug entirely and identify alternative medications.

How long will the dark spots last after the lesions go away?

Post-inflammatory hyperpigmentation typically fades within 3-6 months in lighter skin types and may persist 6-12 months or longer in darker skin types. Avoiding sun exposure and using SPF 30+ sunscreen can prevent further darkening. Topical depigmenting agents (hydroquinone) may help but are not always effective.

Can FDE become Stevens-Johnson Syndrome?

FDE and Stevens-Johnson Syndrome (SJS) are distinct conditions. FDE recurs predictably at the same sites with mild systemic symptoms. SJS involves widespread mucocutaneous involvement with fever and systemic toxicity. While the same drugs can cause both (e.g., TMP-SMX), FDE does not "progress" to SJS with continued drug use. However, taking the drug again raises the small risk of evolving into a more severe reaction.

References